Prospective Multicenter Cohort Study for the Development and Evaluation of Risk Stratification Tools for Lung Cancers and Their Postoperative Recurrences Using Multimodal Clinical, Radiological, Tissue and Longitudinal Biological Phenotyping Among People at Risk of Lung Cancer

NCT07042867 | Not Yet Recruiting

• 1 other identifier: 2024-A02828-39
• Study Type: interventional
• Target: 900
• Locations: 0 countries
• Sites: N/A

Brief Summary

Interventional study with minimal risks and constraints, involving annual assessment of the prevalence and incidence of lung cancer using low-dose contrast-free thoracic CT scans, immunological, inflammatory, metabolic, blood nucleic acid and digestive microbiota profiles; systematic proposal of smoking cessation for active smokers, or assistance in maintaining cessation This is a prospective validation study of risk stratification tools still under development. The results of this study will be used to design medical devices (software integrating risk stratification tools), which will then be evaluated as part of subsequent Clinical Investigations.

Conditions

Lung Cancer (Diagnosis)

Keywords

lung cancer, lung nodules, prevention, dignosis, low dose scan, biomarkers

Outcome Measures

Primary Outcomes (1)

• Sensitivity and specificity of the radiomics algorithm for characterizing benign vs. malignant lung lesions.

  30 months

Secondary Outcomes (6)

• Sensitivity and specificity of minimal biological panel based on markers of inflammation, immunity, blood metabolism and stool metagenomics for characterization of benign vs. malignant lung lesions.

  30 months

• Sensitivity and specificity of new biomarkers including specific antibodies and circulating nucleic acids for characterization of benign vs. malignant lung lesions.

  30 months

• Sensitivity and specificity of a patho-radiomic-based algorithm quantifying the risk of recurrence of operated lung cancers.

  30 months

• Sensitivity and specificity of minimal and novel biomarker panels for the prediction of postoperative lung cancer recurrence.

  30 months

• Description of biomarker panels among people not eligible for lung cancer screening.

  30 months

Study Arms (3)

Group A: patients with a nodule or lung mass identified on CT scan, with no indication of an immedi

OTHER

patients with a nodule or lung mass identified on CT scan, with no indication of an immediate diagnostic workup

Biological: biobanking; Radiation: low dose scan

Group B: cohort of patients with a nodule or lung mass identified on CT with an indication for biops

OTHER

cohort of patients with a nodule or lung mass identified on CT with an indication for biopsy or excision surgery

Biological: biobanking; Radiation: low dose scan

Group C: Individuals with at least one risk factor for lung cancer and no prior lung imaging, but no

OTHER

Individuals with at least one risk factor for lung cancer and no prior lung imaging, but not eligible for lung cancer screening according to INCa criteria.

Biological: biobanking; Radiation: low dose scan

Interventions

biobanking BIOLOGICAL

blood draw at each time point

Group A: patients with a nodule or lung mass identified on CT scan, with no indication of an immedi; Group B: cohort of patients with a nodule or lung mass identified on CT with an indication for biops; Group C: Individuals with at least one risk factor for lung cancer and no prior lung imaging, but no

low dose scan RADIATION

low dose lung scan will be performed at each timepoint

Group A: patients with a nodule or lung mass identified on CT scan, with no indication of an immedi; Group B: cohort of patients with a nodule or lung mass identified on CT with an indication for biops; Group C: Individuals with at least one risk factor for lung cancer and no prior lung imaging, but no

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Group A:
• CI 1- Age \> 18 years AND CI2a- Person eligible for screening with a nodule or lung mass with no indication of reassessment by CT scan before the next round of screening, as recommended by the multidisciplinary consultation meeting OR CI2b- Person not eligible for screening with a nodule or lung mass with an indication for reassessment by CT scan without immediate diagnostic workup (PET scan, biopsy, surgery) as determined by the multidisciplinary consultation meeting.
• Group B CI1- Age \> 18 years AND CI2- Indication for biopsy or surgical excision for diagnostic and therapeutic purposes proposed in a multidisciplinary consultation meeting.
• Group C CI1a- Age 40 - 75 and daily smoking for at least 20 years initiated before age 15 OR CI1b- Age 50 - 75 and passive smoking for at least 20 years in a closed environment (family or workplace) OR CI1c- Age 50 - 75 and smoking 10 cig/d for 30 years or 15 cig/d for 25 years or 20 pack-years with no withdrawal period OR
• CI1d- Age 50 - 75 and daily smoking for at least 10 years combined with at least one other lung cancer risk factor from among :
• Self-reported daily passive smoking for \> 10 years (smokers at home or in enclosed environments)
• Self-reported exposure to a lung carcinogen: Radon, coal smoke, soot, diesel, nickel, beryllium, arsenic, cadmium, asbestos
• st-degree family history of lung cancer
• Personal history of tobacco-related disease, including atheromatous cardiovascular disease, COPD or emphysema, cancer not monitored by chest imaging
• weekly use of cannabis (joints) for 10 years
• All Groups:
• Have signed an informed consent form
• Affiliated with or benefiting from a social security scheme
• Male or female

You may not qualify if:

• Goups A and B Contraindication to lung biopsy or thoracic surgery for diagnostic or therapeutic purposes
• Group C Eligible for lung cancer screening according to INCa\* criteria
• Previous cancer \< 5 years (except carcinoma in situ of the uterine cervix, basal cell carcinoma of the skin, non-invasive urothelial carcinoma treated for curative purposes without CT lung surveillance, prostate cancer with undiagnosable PSA)
• Symptoms of lung cancer (involuntary weight loss \> 10% of usual weight in 1 year, hemoptysis)
• Known history of pulmonary nodule requiring specialized follow-up
• History of pulmonary fibrosis or pulmonary hypertension
• Active pulmonary parenchymal infection
• Severe cardiac or respiratory insufficiency (rest dyspnea)
• Performance status (WHO) 2, 3 or 4
• All Groups
• patient privé de liberté
• patient sous tutelle ou curatelle
• femmes enceintes ou allaitantes
• patient dans l'incapacité d'effectuer le suivi de 30 mois

Sponsors & Collaborators

• Assistance Publique Hopitaux De Marseille: lead

MeSH Terms

Conditions

Lung Neoplasms; Disease

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• David Boulate, Professor of Medicine

  Assistance Publique Hopitaux De Marseille

  PRINCIPAL INVESTIGATOR

Central Study Contacts

David Boulate, Professor

CONTACT

+33 491966018; david.boulate@ap-hm.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 20, 2025
• First Posted: June 29, 2025
• Study Start: July 15, 2025
• Primary Completion (Estimated): January 15, 2028
• Study Completion (Estimated): January 15, 2028
• Last Updated: June 29, 2025

Record last verified: 2025-06